

May 2021 Prioritisation Decisions

Twice a year NHS England makes decisions on which new specialised treatments should be routinely commissioned. The decisions are based on advice from the [Clinical Priorities Advisory Group \(CPAG\)](#), which is made up of doctors, health experts, and patient representatives, and taken by the NHS England Board.

As a result of robust commercial negotiations we are pleased to be able to confirm that all treatments considered in this latest round (May 2021) were affordable within the fixed budget and will, therefore, be commissioned for routine use.

The treatments are:

- **Baricitinib** for use in monogenic interferonopathies (adults and children 2 years and over)
- **Vismodegib** for adults with either Gorlin syndrome or non-Gorlin syndrome related multiple basal cell carcinomas (adults)
- **Brachytherapy** dose escalation with external beam radiotherapy for intermediate- and high-risk localised prostate cancer (adults)
- **Extracorporeal** membrane oxygenation (ECMO) as a bridge to lung transplant (all ages)
- **Abatacept** for treatment of severe treatment-resistant morphea (localised scleroderma) (adults and children over 2 years)
- **Mercaptamine hydrochloride** for corneal cystine deposits in people aged older than 2 years

NHS England is committed to helping patients with rare diseases by funding as many treatments as it can from the available budget at the time.

For more information on our prioritisation process, please watch our video: [Making decisions about which new treatments to fund.](#)